Cover Image
市場調查報告書

全球樹突狀細胞癌症疫苗市場、臨床試驗預測

Global Dendritic Cell Cancer Vaccine Market and Clinical Trials Outlook 2023

出版商 KuicK Research 商品編碼 322277
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球樹突狀細胞癌症疫苗市場、臨床試驗預測 Global Dendritic Cell Cancer Vaccine Market and Clinical Trials Outlook 2023
出版日期: 2017年06月09日 內容資訊: 英文 170 Pages
簡介

本報告提供全球樹突狀細胞癌症疫苗市場相關調查分析,市場概要,評估,臨床實驗平台,上市產品,未來的成長機會等系統性資訊。

第1章 腫瘤學的樹突狀細胞疫苗的登場

第2章 對樹突狀細胞的分類

第3章 樹突狀細胞的免疫反應的調節

  • 抗原出現
  • 抗原堆疊
  • 樹突狀細胞來源、子集
  • 成熟
  • 由於刺激的成熟
  • 移動到淋巴節
  • 疫苗接種的準確度
  • 臨床結果
  • 品管
  • 免疫監測

第4章 樹突狀細胞疫苗的準備

  • CD4 T、CD8 T細胞的交叉提示
  • 在原位置 (原位) 的補充、成熟、投入策略
  • NKT細胞的活性化策略

第5章 與其他治療方法的樹突狀細胞疫苗的評估

  • 樹突狀細胞癌症疫苗和單株抗體
  • 樹突狀細胞癌症疫苗和肽系的癌症疫苗
  • 樹突狀細胞癌症疫苗和細胞因子系的癌症疫苗
  • 樹突狀細胞癌症疫苗和抗體藥物的共軛系的癌症疫苗

第6章 樹突狀細胞癌症疫苗市場與臨床考察

  • 樹突狀細胞癌症疫苗接種相關趨勢
  • 樹突狀細胞癌症疫苗開發平台概要

第7章 樹突狀細胞癌症疫苗成長的暗流

第8章 樹突狀細胞癌症疫苗的課題

第9章 未來預測

第10章 樹突狀細胞癌症疫苗的臨床實驗平台:各企業,各適應症,各Phase

  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段

第11章 已上市的樹突狀細胞疫苗臨床考察

第12章 競爭情形

  • 3M Company
  • Activartis
  • Argos Therapeutics
  • Batavia Bioservices
  • Bellicum Pharmaceuticals
  • Creagene
  • DanDrit Biotech
  • DCPrime
  • Dendreon Corporation
  • Elios Therapeutics
  • ImmunoCellular Therapeutics
  • Immunicum
  • Kiromic
  • Medigene
  • Merck
  • Northwest Biotherapeutics
  • Glaxo Smith Kline
  • ImmunoCellular Therapeutics
  • SOTIO
  • Tella Incorporation
  • Theravectys
  • Vaxil BioTherapeutics

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

“Global Dendritic Cell Cancer Vaccine Market and Clinical Trials Outlook 2023” report gives comprehensive insight on various clinical and non-clinical advancements in the global dendritic cell cancer vaccine market. In recent years, dendritic cell cancer vaccines have emerged as new growth frontier for the companies involved in the research and development of drugs for the treatment of cancer. As per report findings, currently there are 53 dendritic cell cancer vaccines in clinical pipeline. Most of the dendritic cell cancer vaccines are in preclinical phase followed by phase-II clinical trials.

“Global Dendritic Cell Cancer Vaccine Market and Clinical Trials Outlook 2023” Highlights:

  • Global Dendritic Cell Cancer Vaccine Market Overview
  • Assessment of Dendritic Vaccines with Other Therapeutic Regimens
  • Global Dendritic Cell Vaccines Clinical Pipeline by Company, Indication and Phase
  • Marketed Dendritic Cell Vaccines Clinical Insight
  • Dendritic Cells Mechanizing Immune Response
  • Future Growth Opportunities

Cancer is the leading cause of death worldwide and with around 18 million to 20 million new cases emerging every year, it takes heavy toll on people life and property. The governments across the globe along with private sectors have invested heavily in cancer therapeutics, which will be on the rising curve given the factors that abnormally increase the concentration of carcinogens in the atmosphere like vehicular emissions, environmental degradation coupled with drastic lifestyle changes like leading a sedentary life, lack of exercise etc.

Meanwhile, the conventional cancer therapeutics has but failed to yield desired result. During chemotherapy or radiation therapy or hormonal treatments which are the working horse of the cancer treatment besides tumor cells, normal surrounding cells are also killed. The necrosis factors associated with the dying normal cells signals inflammatory response to kick in and take the immune system on hyper drive killing tumor cells as well as normal, healthy adjoining cells as a collateral damage. This brings out the biggest irony, that the body instead of fighting off the cancer becomes susceptible to plethora of other life-threatening abnormalities causing high morbidity.

Dendritic cell cancer vaccines have created a niche for themselves in the cancer market, because they enjoy some inherent biochemical properties which could only be envy by their peers. They are the best known antigen presenting cells, as their task is to bind to the antigen peptides with MHC molecules and activate CD4+ T cells or CD8+ T cells to elicit the desired innate and adoptive immunity. Their action with MHC molecule offers dendritic cells, the prerequisite specificity in targeting the tumor associated antigens of various cancer types and its sub-types. This has enabled dendritic cell cancer vaccines to offer a wide domain of therapeutic action.

The recent advancement in in situ dendritic cell production from its progenitor cells, its maturation enabling processes and its delivery techniques has added to their advantage. They are also known to generate memory T cells which could produce a heightened secondary immune response for future encounters with the tumor cells in case of tumor progression. As cancer cells are known to evade immune response by triggering regulatory T cells suppressing the immune system, dendritic cells come to the rescue as it antagonistically acts on immune checkpoint inhibitors like CLAT4 and CD25 mediated immune pathways, thereby breaking the host's immune tolerance.

As dendritic cells are found to have a modulatory effect on almost all the parameters of the immune system, all other types of cancer vaccines are found to be administered in conjugation with dendritic cells cancer vaccine to have a synergistic effect on immune system against tumor growth. With further advancement in immunological studies, dendritic cells cancer vaccine will have a driving effect on cancer therapeutics which will have a lion's share on cancer vaccine market.

Even though some technical concerns existed regarding in situ production of dendritic cells due to its low concentration in peripheral tissues, it has been successfully overcome with engineered dendritic cells which could now be produced in large number for mass scale vaccination programs. Simultaneous administration of regulating factors which facilitate dendritic cell survival and immune-modulator function holds the key for increased efficiency of cancer vaccine based on dendritic cell, the superspecialised sentinels of cancer immunotherapy, the title it truly deserves.

Table of Contents

1. Advent of Dendritic Vaccine in Oncology

2. Cataloging towards Dendritic Cells

3. Dendritic Cells Mechanizing Immune Response

  • 3.1. Antigen Appearance Leads to Cellular Immune Responses
  • 3.2. Stacking of Distinct Antigens over Dendritic Cells
  • 3.3. Dendritic Cells Source and Subsets
  • 3.4. Trail towards Maturation
  • 3.5. Stimulation Initiates Maturation
  • 3.6. Migration to Lymph Node
  • 3.7. Precision of Dendritic Cells Vaccination
  • 3.8. Illustrations of Clinical Results among Varied Cancer
  • 3.9. Quality Control
  • 3.10. Immune Monitoring

4. Equipping Dendritic Cell Vaccines

  • 4.1. Cross Presentation of CD4 T-CD8 T Cells
  • 4.2. Strategies to Recruit, Mature and Load Dendritic Cells In Situ
  • 4.3. Strategies to Activate NKT Cells

5. Assessment of Dendritic Vaccines with Other Therapeutic Regimens

  • 5.1. Dendritic Cell Cancer Vaccine and Monoclonal Antibodies
  • 5.2. Dendritic Cell Cancer Vaccine and Peptide Based Cancer Vaccine
  • 5.3. Dendritic Cell Cancer Vaccine and Cytokine Based Cancer Vaccine
  • 5.4. Dendritic Cell Cancer Vaccine and Antibody Drug Conjugate Based Cancer Vaccine

6. Dendritic Cell Cancer Vaccine Market and Clinical Insight

  • 6.1. Some Trends Involving Dendritic Cells Cancer Vaccination
  • 6.2. Dendritic Cell Cancer Vaccine Pipeline Overview

7. Undercurrents of Dendritic Cancer Vaccine Growth

8. Challenging Milieu for Dendritic Cancer Vaccine

9. Prospective Trajectories for Future

10. Dendritic Cell Vaccines Clinical Pipeline by Company, Indication and Phase

  • 10.1. Research
  • 10.2. Preclinical
  • 10.3. Clinical
  • 10.4. Phase I
  • 10.5. Phase I/II
  • 10.6. Phase II
  • 10.7. Phase II/III
  • 10.8. Phase III

11. Marketed Dendritic Cell Vaccines Clinical Insight

  • 11.1. Sipuleucel-T (Provenge)
  • 11.2. Dendritic Cell Vaccine (CreaVax-HCC,CreaVax-PC and CreaVax-RCC)
  • 11.3. Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

12. Competitve Landscape

  • 12.1. 3M Company
  • 12.2. Activartis
  • 12.3. Argos Therapeutics
  • 12.4. Batavia Bioservices
  • 12.5. Bellicum Pharmaceuticals
  • 12.6. Creagene
  • 12.7. DanDrit Biotech
  • 12.8. DCPrime
  • 12.9. Dendreon Corporation
  • 12.10. Elios Therapeutics
  • 12.11. ImmunoCellular Therapeutics
  • 12.12. Immunicum
  • 12.13. Kiromic
  • 12.14. Medigene
  • 12.15. Merck
  • 12.16. Northwest Biotherapeutics
  • 12.17. Glaxo Smith Kline
  • 12.18. ImmunoCellular Therapeutics
  • 12.19. SOTIO
  • 12.20. Tella Incorporation
  • 12.21. Theravectys
  • 12.22. Vaxil BioTherapeutics

List of Figures:

  • Figure 1-1: Advantages of Dendritic Cell Cancer Vaccine
  • Figure 2-1: Classification of Dendritic Cells
  • Figure 3-1: Principle of Dendritic Cell Cancer Immunotherapy
  • Figure 3-2: The Key Players Intricately Involved in Antigen Presentation and Immune Response Machinery
  • Figure 3-3: Process of Antigen-loading
  • Figure 3-4: Major Life Cycle Events of a Dendritic Cell
  • Figure 3-5: A Diagrammatic Representation of Dendritic Cell Plasticity
  • Figure 3-6: Action of Dendritic Cells on the Various Cancer Forms
  • Figure 4-1: The Arsenals in the Inventory of Dendritic Cells
  • Figure 5-1: Working Principle Targeted By Dendritic Cells and Monoclonal Antibodies
  • Figure 5-2: Working Principle Targeted by Dendritic Cells and Peptide Cancer Vaccines
  • Figure 5-3: Working Principle Targeted by Dendritic Cells and Cytokine Cancer Vaccine
  • Figure 5-4: Working Principle Targeted By Dendritic Cells and Antibody-Drug Conjugates Cancer Vaccines
  • Figure 6-1: Recent Trends in Dendritic Cell Vaccine
  • Figure 6-2: Global - Dendritic Cell Cancer Vaccine Clinical Pipeline by Phase (%), 2017 till 2023
  • Figure 6-3: Global - Dendritic Cell Cancer Vaccine Clinical Pipeline by Phase (Number), 2017 till 2023
  • Figure 6-4: Global andndash; Suspended Dendritic Cell Vaccine in Clinical Pipeline by Phase (%), 2017 till 2023
  • Figure 6-5: Global andndash; Suspended Dendritic Cell Vaccine in Pipeline by Phase (Number), 2017 till 2023
  • Figure 7-1: Factors Driving Dendritic Cell Cancer Vaccine
  • Figure 8-1: Challenges for Dendritic Cell Cancer Vaccine
  • Figure 12-1: Argos Therapeutics- Clinical Pipeline
  • Figure 12-2: Bellicum Pharmaceuticals Clinical Pipeline
  • Figure 12-3: DCPrime Clinical Pipeline
  • Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 12-5: Immunicum Clinical Pipeline
  • Figure 12-6: Medigene Clinical Pipeline
  • Figure 12-7: Northwest Biotherapeutics Clinical Pipeline
  • Figure 12-8: SOTIO Clinical Pipeline
Back to Top